Patent Foramen Ovale Closure for Treating Migraine: A Meta-Analysis

Table 2

Sensitivity analysis of interconversion between the fixed-effects model and random-effects model and exchange of statistical values.

Risk factors	RR or MD 95% CI, value	Exchange of statistic value RR or MD 95% CI, value	Switching model OR or SMD 95% CI, value
Reduction 50% in monthly (N  = 3)	1.5698 [1.0465–2.3548],	1.3187 [1.1710–1.4867],	1.7134 [1.2903–2.2602],
Complete resolution (N  = 3)	3.4327 [0.6625–17.7870],	3.2345 [0.4567–12.5934],	3.0678 [0.7006–18.1714],
Monthly migraine days (N  = 3)	0.2594 [0.0790–0.4398],	0.2531 [0.0789–0.4489],	0.3024 [0.0678–0.4478],
Migraine with aura (N  = 8)	1.5856 [1.0665–2.3575],	1.4356 [1.0345–2.6701],	1.6826 [1.0567–2.3456],

OR: odds ratio; RR: risk ratio; MD: mean difference; SMD: standardized mean difference; CI: confidence interval.